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Objective.Marfan syndrome (MS) is a multisystem disorder caused by a mutation in FBN1 gene. It shares some phenotypic features
with hypermobile Ehlers-Danlos syndrome (EDS) such as joint hypermobility. EDS is a group of inherited heterogenous
multisystem disorders characterized by skin hyperextensibility, atrophic scarring, joint hypermobility, and generalized tissue
fragility. Hypermobile EDS (hEDS) is thought to be the most common type. Recent studies have suggested an association
between connective tissue hypermobility and functional gastrointestinal disorders (FGDs). The aim of this study is to determine
the prevalence of gastrointestinal symptoms in patients with Marfan syndrome and hypermobile EDS. Method. Patients with a
diagnosis of either MS or hEDS attending cardiology or rheumatology outpatients at our hospital were asked to complete SF36
RAND and Rome IV Diagnostic questionnaires. Questionnaires were also completed by patients who are members of Marfan
Association UK. The same questionnaires were also completed by age- and gender-matched controls attending fracture clinic
without existing diagnoses of MS or hEDS. Results. Data were collected from 45 MS patients (12 males and 33 females, age
range 19–41 years, mean 28 years) and 45 hEDS patients (6 males and 39 females, age range 18–32 years, mean 24 years). None
had a previous organic gastrointestinal diagnosis. The control group was matched for age and sex (18 males and 72 females, age
range 18–45, mean 29 years). Both MS and hEDS groups showed a higher prevalence of abdominal symptoms compared to the
control group; however, the hEDS group not only showed a higher prevalence but more frequent and severe symptoms meeting
Rome IV criteria for diagnosis of FGIDs. Nearly half of the hEDS patients met the criteria for more than one FGID. The hEDS
group also scored lower on quality of life (QOL) scores in comparison to either of the other groups with a mean score of 48.6 as
compared to 54.2 in the Marfan group and 78.6 in the control group. Conclusion. FGIDs are reported in both Marfan syndrome
and hypermobile Ehlers-Danlos syndrome but appear to be more common and severe in hEDS. These patients score lower on
quality of life scores as well despite hypermobility being a common feature of both conditions. Further work is needed to
understand the impact of connective tissue disorders on gastrointestinal symptoms.
1. Introduction
Marfan syndrome (MS) is a multisystem disorder caused by a
mutation in FBN1 gene [1]. It shares some phenotypic
features with hypermobile Ehlers-Danlos syndrome (EDS)
such as joint hypermobility [2]. EDS is a group of inherited
heterogenous multisystem disorders characterized by skin
hyperextensibility, atrophic scarring, joint hypermobility,
and generalized tissue fragility [3]. Hypermobile EDS (hEDS)
is thought to be the most common type [4]. Recent studies
have suggested an association between connective tissue
hypermobility and functional gastrointestinal disorders
(FGDs) [5–10].
Gastrointestinal symptoms are reported to be common in
patients with hypermobility; however, much of the recent
interest in this area is focused only on patients with hEDS.
No previous study has compared the prevalence of gastroin-
testinal symptoms in patients with MS and compared to
patients with hEDS. The aim of our study is to use standar-
dised deﬁnitions for all gastrointestinal symptoms using
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Diagnostic Rome IV questionnaire as well as look for the
overall perception of health and well-being using RAND
SF36 questionnaire. We have also investigated the use of
the most commonly used medications which aﬀect gastroin-
testinal function in these groups.
2. Method
Patients attending outpatients at St. George’s Hospital who
had an existing diagnosis of MS or hEDS were asked to com-
plete SF36 RAND and Rome IV Diagnostic questionnaires.
Some patients were recruited with the help of Marfan Associ-
ation UK. All patients completed the questionnaires by
themselves, either in the Outpatients Department or at home,
and returned them by post.
Controls were recruited from outpatients attending the
fracture clinic at St. George’s Hospital, one control being
recruited for each MS and hEDS patient, matched by gender
and age (±10 years). Hypermobility was assessed in these
controls using Beighton criteria, and scores of 4 or less were
included. All patients completed the questionnaires them-
selves while attending clinic. No ﬁnancial or other induce-
ments were given.
All recruited subjects completed the SF36 RAND and
Rome IV Diagnostic questionnaires. Additional questions
regarding ethnicity, smoking and alcohol use, use of medi-
cines, and other medical conditions were added using previ-
ously validated questionnaires. All participants were asked if
they had used antisecretory/antacid therapy or laxatives,
either regularly or on as required basis in the last six months.
The scoring algorithm for Rome IV Diagnostic questionnaire
for adults was used, and a functional gastrointestinal disorder
was said to be present if the criteria were met. The presence of
abdominal pain, constipation, and diarrhoea was investi-
gated separately even if criteria for FGID were not met.
The Rome IV classiﬁcation was followed for various
gastrointestinal symptoms and diagnoses including the
following:
(1) Oesophageal disorders (functional chest pain, func-
tional heartburn, Globus, and functional dysphagia)
(2) Gastroduodenal disorders (functional dyspepsia,
belching disorders, nausea and vomiting disorders,
and rumination syndrome)
(3) Bowel disorders (irritable bowel syndrome (IBS),
functional constipation, functional diarrhoea, func-
tional abdominal bloating/distension, and unspeci-
ﬁed functional bowel disorder)
(4) Centrally mediated abdominal pain syndrome
(5) Functional biliary pain
(6) Anorectal disorders (faecal incontinence and func-
tional anorectal pain)
Functional chest pain was deﬁned as retrosternal chest
pain or discomfort at least weekly with no heartburn or
dysphagia. Functional heartburn was deﬁned as burning
retrosternal discomfort or pain with no relief from antisecre-
tory therapy. Globus was deﬁned as persistent or intermit-
tent, nonpainful sensation of a lump or foreign body in the
throat with the absence of dysphagia or heartburn. Func-
tional dysphagia was deﬁned as sense of solid and/or liquid
foods sticking, lodging, or passing abnormally through the
oesophagus in the absence of organic disorders.
Functional dyspepsia was deﬁned as postprandial full-
ness, early satiation, epigastric pain, or burning, severe
enough to impact on usual activities or prevent ﬁnishing
a regular size meal. Functional belching was deﬁned as
belching, severe enough to impact on usual activities, from
the oesophagus or stomach more than 3 days a week.
Nausea and vomiting disorders were deﬁned as weekly
nausea or vomiting episodes, severe enough to impact on
usual activities. Rumination syndrome was deﬁned as per-
sistent or recurrent regurgitation of recently ingested food
into the mouth with subsequent spitting or remastication
and swallowing.
IBS was deﬁned as recurrent abdominal pain related to
defecation and associated with a change in frequency or form
of stool. IBS subtypes (IBS-C, IBS-D, IBS-M, and IBS-U)
were classiﬁed based on patient’s perception of the usual con-
sistency of abnormal stools, according to Bristol stool scale.
Functional constipation was deﬁned as bowel opening asso-
ciated with two or more of straining, type 1-2 (Bristol stool
scale) stools, sensation of incomplete evacuation, sensation
of anorectal obstruction, manual manoeuvres to facilitate
defecation, fewer than three spontaneous stools per week,
and absence of loose stools. Functional diarrhoea was deﬁned
as the presence of loose, watery stools (type 5-6 Bristol stool
scale) without predominant abdominal pain or bloating.
Functional abdominal bloating/distension was deﬁned as
recurrent bloating or distension at least weekly where bloat-
ing predominates all other symptoms. Unspeciﬁed functional
bowel disorder was deﬁned as the presence of symptoms of
abdominal pain, constipation, diarrhoea, or bloating which
do not meet criteria for other conditions.
Centrally mediated abdominal pain syndrome was
deﬁned as continuous or nearly continuous abdominal pain
with no (or occasional) relationship of pain to physiological
events such as eating, defecation, or periods. Functional bili-
ary pain was deﬁned as pain in the epigastrium and/or right
upper quadrant that builds up to a steady level, lasts 30
minutes or longer, occurring at diﬀerent intervals, severe
enough to interrupt usual activities and not related to bowel
movements, posture change, or acid suppression.
Faecal incontinence was deﬁned as recurrent uncon-
trolled passage of faecal material. Functional anorectal pain
was deﬁned as chronic or recurrent rectal pain or aching with
episodes lasting 30 minutes or longer.
All participants completed the SF36 Quality of Life
questionnaire. Mean scores out of 100 (where 0 was the
worst outcome on the scale and 100 was the best) for all
groups were calculated for each of the eight domains, that
is, physical functioning, role limitations due to physical
health, role limitations due to emotional problems, level
of energy/fatigue, emotional well-being, social functioning,
pain, and general health.
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2.1. Statistical Analyses. Statistical analyses were performed
using the IBM Statistical Package for the Social Science
(SPSS) software version 25 (IBM SPSS Inc., Chicago, IL).
The Fisher’s exact test and Chi-squared test were used for
comparing categorical variables. Independent sample t-test
values were used to compare the mean scores in diﬀerent
modalities of SF36 questionnaire. As multiple comparisons
were made, probability values of <0.05 were thought to be
statistically signiﬁcant.
2.2. Ethical Considerations. The study protocol was approved
by the South West-Central Bristol Research Ethics Commit-
tee and NHS Health Research Authority UK.
3. Results
90 patients and 90 controls were included in this study. Data
was collected from 45 MS patients (12 males and 33 females,
age 19–41, mean 28 years) with no organic gastrointestinal
diagnosis. Data was collected from 45 hEDS patients (6 males
and 39 females, age 18–32, mean 24 years) with no organic
gastrointestinal diagnosis.
3.1. Gastrointestinal Symptoms in MS/hEDS Patients. Com-
bining the MS and hEDS patients together, these patients
were more likely to report a wide range of gastrointestinal
symptoms compared to controls (Table 1).
Abdominal pain, bowel symptoms, heartburn, dyspepsia,
and dysphagia were all signiﬁcantly more common in the
combined hypermobile group compared with controls. Med-
ication use was also signiﬁcantly more common in this group.
3.2. Gastrointestinal Symptoms in MS.More Marfan patients
reported abdominal pain, diarrhoea, and constipation than
controls; however, only symptom of abdominal pain was
thought to be statistically signiﬁcant. The use of antisecretory
Table 1: Gastrointestinal symptoms in MS/hEDS patients compared with controls.
Controls MS/hEDS patients P value (Fisher’s exact test)
Number 90 90
M : F 18 : 72 18 : 72
Symptoms
Abdominal pain 25 55 <0.0001∗∗∗
Diarrhoea 8 30 <0.0001∗∗∗
Constipation 15 49 <0.0001∗∗∗
Medicines
Antisecretory/antacids 17 48 <0.0001∗∗∗
Laxatives 13 46 <0.0001∗∗∗
Oesophageal disorders
Functional chest pain 1 6 0.1177
Functional heartburn 11 30 0.0012∗∗
Globus 1 3 0.6208
Functional dysphagia 3 13 0.016∗
Gastroduodenal disorders
Functional dyspepsia 7 25 0.0007∗∗∗
Belching disorders 4 10 0.016∗
Nausea and vomiting disorders 1 4 0.3680
Rumination syndrome 1 3 0.6208
Bowel disorders
Irritable bowel syndrome 6 21 0.0029∗∗
Functional constipation 11 32 0.0004∗∗∗
Functional diarrhoea 5 19 0.0036∗∗
Functional abdominal bloating/distension 6 23 0.0009∗∗∗
Unspeciﬁed functional bowel disorder 22 50 <0.0001∗∗∗
Centrally mediated abdominal pain syndrome 3 9 0.1324
Functional biliary pain 1 1 1
Anorectal disorders
Faecal incontinence 1 2 1
Functional anorectal pain 2 4 0.6822
∗P < 0 05; ∗∗P < 0 01; ∗∗∗P < 0 001.
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therapy and laxative was also reported in more MS patients
than controls, but this did not reach statistical signiﬁcance
(Table 2).
3.3. Gastrointestinal Symptoms and Diagnoses in hEDS
Patients (Table 3).AllGI symptoms anduse ofmedicines were
considerably higher in the hEDS groupmeeting statistical sig-
niﬁcance for all three symptoms and use of medicines. FGIDs
were also more frequently found in hEDS group meeting
statistical signiﬁcance for functional heartburn, functional
dysphagia, functional dyspepsia, irritable bowel syndrome,
functional constipation, functional diarrhoea, functional
abdominal bloating, and unspeciﬁed bowel disorder (Table 3).
3.4. Perception of Health andWell-Being. The SF36 Quality of
Life questionnaire generates a mean score out of 100 (where 0
was the worst outcome on the scale and 100 was the best)
for eight domains: physical functioning, role limitations
due to physical health, role limitations due to emotional
problems, level of energy/fatigue, emotional well-being,
social functioning, pain, and general health. The mean scores
across all domains of MS patients were compared with con-
trols showing statistical signiﬁcance in most domains
(Table 4). Similarly, the mean scores of hEDS patients
showed statistical signiﬁcance in almost all domains when
compared to controls (Table 5). The hEDS group, however,
scored the lowest on all domains of this questionnaire.
4. Discussion
This is the ﬁrst study of its kind showing that connective tis-
sue hypermobile syndromes are associated with a signiﬁcant
number of gastrointestinal symptoms compared to control
patients. Despite the many phenotypic similarities, MS and
hEDS exhibit diﬀerent symptom complexes. The burden of
functional gastrointestinal symptoms in MS in comparison
with hEDS has never been studied and compared. Individuals
with hEDS suﬀer a greater impairment to general well-being
than MS patients.
Table 2: Gastrointestinal symptoms in MS patients compared with controls.
Control MS P value (Fisher’s exact test)
Number 45 45
M : F 12 : 33 12 : 33
Symptoms
Abdominal pain 13 24 0.0315∗
Diarrhoea 4 9 0.2297
Constipation 8 16 0.0941
Medicines
Antisecretory/antacids 9 11 0.8004
Laxatives 6 12 0.1868
Oesophageal disorders
Functional chest pain 0 2 0.4944
Functional heartburn 5 9 0.3837
Globus 0 1 1
Functional dysphagia 1 4 1
Gastroduodenal disorders
Functional dyspepsia 3 8 0.1966
Belching disorders 2 3 0.6766
Nausea and vomiting disorders 0 1 1
Rumination syndrome 0 1 —
Bowel disorders
Irritable bowel syndrome 3 6 0.7136
Functional constipation 5 9 0.3837
Functional diarrhoea 2 7 1
Functional abdominal bloating/distension 3 9 0.1184
Unspeciﬁed functional bowel disorder 10 23 0.1760
Centrally mediated abdominal pain syndrome 1 2 0.6164
Functional biliary pain 0 0
Anorectal disorders
Faecal incontinence 0 1
Functional anorectal pain 1 2 1
∗P < 0 05; ∗∗P < 0 01; ∗∗∗P < 0 001.
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Table 3: Gastrointestinal symptoms in hEDS patients compared with controls.
Control hEDS P value (Fisher’s exact test)
Number 45 45
M : F 6 : 39 6 : 39
Symptoms
Abdominal pain 12 31 <0.0001∗∗∗
Diarrhoea 4 21 <0.0001∗∗∗
Constipation 7 33 <0.0001∗∗∗
Medicines
Antisecretory/antacids 8 37 <0.0001∗∗∗
Laxatives 7 34 <0.0001∗∗∗
Oesophageal disorders
Functional chest pain 1 4 0.3607
Functional heartburn 6 21 0.0011∗∗
Globus 1 2 1
Functional dysphagia 2 9 0.01∗
Gastroduodenal disorders
Functional dyspepsia 4 17 0.0291∗
Belching disorders 2 7 0.2663
Nausea and vomiting disorders 1 3 0.6164
Rumination syndrome 1 2 0.6164
Bowel disorders
Irritable bowel syndrome 3 15 0.0014∗∗
Functional constipation 6 23 0.0002∗∗
Functional diarrhoea 3 12 0.0014∗∗
Functional abdominal bloating/distension 3 14 0.0059∗∗
Unspeciﬁed functional bowel disorder 12 27 <0.0001∗∗∗
Centrally mediated abdominal pain syndrome 2 7 0.2663
Functional biliary pain 1 1 1
Anorectal disorders
Faecal incontinence 1 1 1
Functional anorectal pain 1 2 0.6164
∗P < 0 05; ∗∗P < 0 01; ∗∗∗P < 0 001.
Table 4: Quality of life scores in MS patients.
Controls (mean scores) MS (mean scores) Independent sample t-test
Physical functioning 100.0 80.0 0.0012∗∗
Role limitations due to physical health 100.0 50.0 <0.0001∗∗∗
Role limitations due to emotional problems 100.0 100.0 1
Level of energy/fatigue 95.0 45.0 <0.0001∗∗∗
Emotional well-being 100.0 68.0 <0.0001∗∗∗
Social functioning 87.5 50.0 <0.0001∗∗∗
Pain 77.5 67.5 0.1732
General health 100 30.0 <0.0001∗∗∗
∗P < 0 05; ∗∗P < 0 01; ∗∗∗P < 0 001.
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Marfan syndrome is a spectrum of heritable disorders of
connective tissue with a high degree of clinical variability. It
has an autosomal dominant mode of transmission mainly
aﬀecting the connective tissue protein ﬁbrillin. The defect
itself has been isolated to the FBN1 gene on chromosome
15, which codes for the connective tissue protein ﬁbrillin
[11]. The most serious and common complications of
Marfan syndrome are usually cardiovascular, skeletal, pul-
monary, and ocular. Aortic root dilatation and dissection
[12] are perhaps the most serious manifestations whereas
skeletal deformities [13] including thoracolumbar scoliosis,
thoracic lordosis, and pectus excavatum can lead to pulmo-
nary problems [14] if left untreated. In addition, ocular
problems such as superior dislocation of the lens, retinal
detachment, myopia, glaucoma, and cataracts are common
ﬁndings and can lead to blindness if remain unrecognized
[15–17]. The diagnosis of Marfan syndrome is based on fam-
ily history, the presence of certain clinical features such as
aortic root dilatation and ectopia lentis, and genetic testing
for FBN1. The revised Ghent criteria for diagnosing Marfan
syndrome were published in 2010 [18, 19].
A variety of large surgical publications have highlighted
the anatomical or structural complications involving the gas-
trointestinal tract in patients with Marfan syndrome [20–32];
however, there have not been many studies looking at GI
symptoms in these patients.
Ehlers-Danlos syndrome is described as a group of
inherited noninﬂammatory connective tissue disorders pri-
marily caused by a defect in the synthesis of collagen. The
syndrome derives its name from clinical case reports pre-
sented by 2 physicians: Edvard Ehlers, aDanish dermatologist
in 1901, and Henri-Alexandre Danlos, a French physician in
1908. The types of EDS have traditionally been classiﬁed
according to the Revised Villefranche Nosology presented in
1997 [33].
The current classiﬁcation of EDS is based on the 2017
international classiﬁcation of Ehlers-Danlos syndrome which
includes the traditional six types as well as other rarer types
[34]. All these types share some clinical manifestations such
as joint laxity, soft skin, and easy bruising; however, each type
is thought to involve a unique defect in connective tissue,
although not all the genes responsible for causing EDS have
been found. The hypermobile and classical types are thought
to be much more common than the other types. Diagnosis is
mainly clinical using Beighton criteria for joint hypermobil-
ity in the presence of symptoms of skin elasticity and easy
bruising. Skin histopathology and molecular genetics can be
helpful in diagnosis.
One of the ﬁrst descriptions of gastrointestinal involve-
ment in EDS was an observational study published in 1969
[35]. However, more recently, several published studies have
shown that there is a high prevalence of functional gastroin-
testinal symptoms in Ehlers-Danlos syndrome whereas more
catastrophic gastrointestinal complications remain relatively
rare. Structural abnormalities have been reported in up to
20% of individuals and functional gastrointestinal symptoms
in up to 75% [10, 36]. A retrospective study from Mayo
Clinic including all Ehlers-Danlos syndrome subtypes
reported gastrointestinal symptoms in 66 percent of patients
over a 20-year period. The most commonly reported GI
symptoms were abdominal pain (56.1%), nausea (42.3%),
constipation (38.6%), heartburn (37.6%), and irritable bowel
syndrome-like symptoms (27.5%); however, all gastrointesti-
nal symptoms were more common in the hypermobility sub-
type. A review of investigations carried out in this cohort
showed nearly 40 percent of patients had either hiatus hernia,
erosive reﬂux oesophagitis, or gastritis identiﬁed on OGD.
Gastrointestinal motility was aﬀected with abnormal gastric
emptying in 25 percent and abnormal colonic transit in 30
percent of their patients. The use of medicines was also
higher as compared to the general population with 38 percent
of their group using PPI on a regular basis and another 23
percent using laxatives [36]. Some studies have shown the
prevalence of functional gastrointestinal disorders to be
much higher up to 84 percent with nearly half of the studied
population reporting irritable bowel syndrome and nearly
two-thirds of the population reporting symptoms of gastro-
oesophageal reﬂux [37].
Symptoms of functional gastrointestinal disorders appear
to be more prevalent in the hypermobility subtype of Ehlers-
Danlos syndrome. A comparison of patients aﬀected by joint
hypermobility syndrome/hypermobile Ehlers-Danlos syn-
drome with matched controls showed that all gastrointestinal
symptoms were more common in this group and aﬀected the
quality of life adversely [38]. The association between joint
hypermobility and functional gastrointestinal is increasingly
Table 5: Quality of life scores in hEDS patients.
Controls (mean scores) hEDS (mean scores) Independent sample t-test
Physical functioning 100.0 60.0 <0.0001∗∗∗
Role limitations due to physical health 100.0 50.0 <0.0001∗∗∗
Role limitations due to emotional problems 100.0 50.0 <0.0001∗∗∗
Level of energy/fatigue 95.0 30.0 <0.0001∗∗∗
Emotional well-being 100.0 50.0 <0.0001∗∗∗
Social functioning 87.5 50.0 <0.0001∗∗∗
Pain 77.5 50.0 0.0251∗
General health 100 45.0 <0.0001∗∗∗
∗P < 0 05; ∗∗P < 0 01; ∗∗∗P < 0 001.
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being recognized although the reasons for that remain unclear
[7]. Joint hypermobility appears to be commoner in patients
attending gastroenterology clinics for functional disorders
than in patients attending for organic disorders [6].
In this study, patients with hypermobility reported a wide
range of gastrointestinal symptoms, frequently met the
criteria for the diagnosis of functional gastrointestinal disor-
ders, and showed increased use of medications for gastroin-
testinal symptoms. These appear to be more common in
hypermobile Ehlers-Danlos syndrome patients than in
Marfan syndrome patients. Both groups scored lower than
controls on quality of life indicators; however, hEDS patients
had lower mean scores as compared to MS patients.
However, our study does have some limitations. The
sample size is small, and although individuals with a known
organic gastrointestinal diagnosis were excluded, undiag-
nosed conditions may have been present. Finally, although
it would be expected that all MS patients are under secondary
or tertiary care, it is likely that only the severe hEDS would be
under rheumatology specialist care. This selection bias might
explain the more severe symptoms in this group compared to
the MS group.
A greater understanding of functional gastrointestinal
symptoms in patients with connective tissue disorders may
give further understanding to the aetiology of gastrointestinal
symptoms in individuals not formally diagnosed with con-
nective tissue abnormalities and may give insight into the
causes of functional gastrointestinal disorders and irritable
bowel syndrome.
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